Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite Sustained, statistically significant reduction in sorbitol in...

Related Keywords

Maeve Conneighton ,Advanz Pharma ,Exchange Commission ,Therapeutics Inc ,Drug Administration ,European Medicines Agency ,Health Index ,Twitter ,Nasdaq ,Sorbitol Dehydrogenase ,Aldose Reductase Inhibitor ,New Drug Application ,Analysis Results ,Conference Call ,Applied Therapeutics ,Events Page ,Investor Relations ,Applied Therapeutic ,Dehydrogenase Deficiency ,Aldose Reductase ,Orphan Medicinal Product Designation ,Orphan Drug Designation ,Pediatric Rare Disease ,Fast Track ,Diabetic Cardiomyopathy ,Private Securities Litigation Reform Act ,Markets ,